Canary Staked INJ ETF Secures Nasdaq Listing Approval

iconCrypto Economy
Share
AI summary iconSummary
Canary Capital’s Staked INJ ETF has received Nasdaq listing approval under the ticker INJC. The fund offers exposure to Injective (INJ) with at least 90% staked holdings, managed by BitGo as custodian and a 1.10% annual fee. The Injective Foundation plans to buy up to $15 million in seed shares, but no subscriptions have been finalized. This listing event strategy marks a key step in ETF news trading for institutional investors.

TL;DR

  • Canary Capital’s Staked INJ ETF secured Nasdaq listing approval under ticker INJC, advancing a product designed to combine Injective exposure with staking rewards.
  • The fund plans to stake at least 90% of its INJ holdings under normal conditions, with BitGo as custodian and a 1.10% sponsor fee.
  • The Injective Foundation indicated plans to buy up to $15 million in seed shares, while listing approval alone does not establish investor demand.

Canary Capital’s Staked INJ ETF has secured approval to list on Nasdaq under the ticker INJC, advancing a product designed to combine direct Injective exposure with staking rewards. In an official Injective post, the network said the ETF targets staking 90% of its institutional INJ holdings. The approval moves a regulated Injective investment vehicle closer to public-market access while preserving staking as a core feature of the structure.

Canary’s INJC ETF Combines Spot Exposure and Staking

The approval was disclosed through a November 3 Form 8-A12B filing registering the fund’s common shares for Nasdaq listing. The product is designed to hold INJ directly, with BitGo serving as custodian, while selected providers handle validator operations. INJC is structured to give brokerage investors exposure to both INJ’s market value and network rewards without requiring them to manage wallets or token delegation themselves, building on Canary’s earlier Staked INJ ETF filing.

Canary Capital’s Staked INJ ETF secured Nasdaq listing approval

Under normal conditions, Canary plans to stake at least 90% of the trust’s INJ holdings. The prospectus sets a 1.10% annual sponsor fee, while staking rewards can vary with network conditions and are not guaranteed. Injective’s 21-day unbonding period also creates a liquidity constraint because tokens leaving staking cannot immediately be transferred. The fund therefore pairs yield generation with operational liquidity requirements, a balance already detailed in Canary’s native staking structure.

The listing approval represents a step from the product’s earlier regulatory path. Canary initially pursued a Cboe listing before moving the fund to Nasdaq under INJC. The Injective Foundation has also indicated plans to purchase up to $15 million in seed shares, although the filing cited in the reference showed no completed subscriptions or institutional inflows. A listing approval establishes the exchange arrangement but does not itself demonstrate investor demand or capital entering the fund, following the earlier Cboe listing proposal.

The structure reflects a broader effort to package proof-of-stake assets inside regulated market products while retaining network economics. Investors would gain access through brokerage accounts rather than holding INJ directly, while staking activity remains handled inside the trust. INJC’s differentiating feature is its attempt to combine regulated exchange access with protocol-level staking rewards, extending Injective’s institutional market infrastructure into an exchange-traded format. The remaining questions center on liquidity, staking returns and investor demand once shares become available to the market.

Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information. Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.